Last reviewed · How we verify
Platinum-containing Salvage Chemotherapy
Platinum-containing Salvage Chemotherapy is a Platinum-based chemotherapy agent Small molecule drug developed by Kite, A Gilead Company. It is currently in Phase 3 development for Relapsed or refractory lymphoma (salvage therapy), Other platinum-sensitive malignancies in salvage setting.
Platinum-containing chemotherapy agents work by forming DNA adducts that cross-link DNA strands, preventing replication and transcription, thereby inducing cancer cell death.
Platinum-containing chemotherapy agents work by forming DNA adducts that cross-link DNA strands, preventing replication and transcription, thereby inducing cancer cell death. Used for Relapsed or refractory lymphoma (salvage therapy), Other platinum-sensitive malignancies in salvage setting.
At a glance
| Generic name | Platinum-containing Salvage Chemotherapy |
|---|---|
| Sponsor | Kite, A Gilead Company |
| Drug class | Platinum-based chemotherapy agent |
| Target | DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Platinum compounds (such as cisplatin, carboplatin, or oxaliplatin) bind to DNA and form inter- and intra-strand crosslinks, which block DNA synthesis and repair mechanisms. This leads to apoptosis in rapidly dividing cancer cells. In a salvage setting, these agents are used in patients who have relapsed or are refractory to prior chemotherapy regimens.
Approved indications
- Relapsed or refractory lymphoma (salvage therapy)
- Other platinum-sensitive malignancies in salvage setting
Common side effects
- Myelosuppression (neutropenia, thrombocytopenia, anemia)
- Nausea and vomiting
- Nephrotoxicity
- Ototoxicity
- Peripheral neuropathy
- Mucositis
Key clinical trials
- Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma (PHASE3)
- The Efficacy of Salvage Surgery in Patients With Residual Tumor After Concurrent Chemoradiation for Locally Advanced Cervical Cancer. (NA)
- Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Platinum-containing Salvage Chemotherapy CI brief — competitive landscape report
- Platinum-containing Salvage Chemotherapy updates RSS · CI watch RSS
- Kite, A Gilead Company portfolio CI
Frequently asked questions about Platinum-containing Salvage Chemotherapy
What is Platinum-containing Salvage Chemotherapy?
How does Platinum-containing Salvage Chemotherapy work?
What is Platinum-containing Salvage Chemotherapy used for?
Who makes Platinum-containing Salvage Chemotherapy?
What drug class is Platinum-containing Salvage Chemotherapy in?
What development phase is Platinum-containing Salvage Chemotherapy in?
What are the side effects of Platinum-containing Salvage Chemotherapy?
What does Platinum-containing Salvage Chemotherapy target?
Related
- Drug class: All Platinum-based chemotherapy agent drugs
- Target: All drugs targeting DNA
- Manufacturer: Kite, A Gilead Company — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Relapsed or refractory lymphoma (salvage therapy)
- Indication: Drugs for Other platinum-sensitive malignancies in salvage setting
- Compare: Platinum-containing Salvage Chemotherapy vs similar drugs
- Pricing: Platinum-containing Salvage Chemotherapy cost, discount & access